Clinical performance of an IGF1 LC-MS/MS assay and associated normative dataset in routine endocrinology
Open Access
- 27 February 2026
- journal article
- research article
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 194 (3) , 347-356
Abstract
Background: Accurate interpretation of insulin-like growth factor-1 (IGF1) requires both analytically robust measurement and appropriate reference data. Most available IGF1 normative datasets are based on ligand-binding assays (LBA), limiting their applicability to liquid chromatography-tandem mass spectrometry (LC-MS/MS) methods that provide higher analytical specificity. Objective: To evaluate the clinical performance of an in-house developed LC-MS/MS IGF1 assay in combination with a method-matched normative dataset derived from the Dutch Lifelines cohort, and to compare it with a commonly used LBA. Methods: Paired IGF1 results (n = 2057) were obtained using LC-MS/MS and the IDS iSYS LBA. Standard deviation scores (SDS) were calculated using assay-specific normative datasets. Agreement was assessed by regression, Bland-Altman, and weighted Cohen's κ analyses. Clinical validity was evaluated by comparing extreme SDS values with diagnostic categories adjudicated by endocrinologists. Results: The LC-MS/MS method showed a proportional bias of −27% versus IDS iSYS and yielded symmetrically distributed SDS around zero, whereas IDS iSYS results were positively skewed. Categorical agreement was fair (κ = 0.39). LC-MS/MS-derived SDS corresponded more closely with clinical diagnoses across adult and pediatric groups, including acromegaly, growth hormone (GH) deficiency, and GH replacement therapy. Conclusions: Our LC-MS/MS IGF1 assay integrated with its own population-based normative dataset demonstrated superior alignment with clinical assessment compared with LBA results. In our setting, this method provides a clinically reliable benchmark for IGF1 interpretation and may serve as a reference for IGF1 harmonization and broader adoption of the Lifelines normative dataset in routine endocrinology.Keywords
Funding Information
- Pfizer
- Ministerie van Volksgezondheid, Welzijn en Sport
- Universitair Medisch Centrum Groningen
- Rijksuniversiteit Groningen
This publication has 36 references indexed in Scilit:
- A validated liquid chromatography-tandem mass spectrometry assay for simultaneous quantitation of intact IGF-1 and IGF-2 in human serumJournal of Chromatography B, 2025
- The impact of different calibration matrices on the determination of insulin-like growth factor 1 by high-resolution-LC-MS in acromegalic and growth hormone deficient patientsClinical Biochemistry, 2023
- Discordance of insulin-like growth factor-1 results and interpretation on four different platformsClinica Chimica Acta, 2022
- Bias in IGF-1 concentrations and interpretation across three different clinical laboratory assaysClinical Biochemistry, 2022
- An antibody-free LC-MS/MS method for the quantification of intact insulin-like growth factors 1 and 2 in human plasmaAnalytical and Bioanalytical Chemistry, 2021
- Effects of GH/IGF axis on bone and cartilageMolecular and Cellular Endocrinology, 2021
- A high-throughput assay for the quantification of intact Insulin-like Growth Factor I in human serum using online SPE-LC-HRMSClinica Chimica Acta, 2020
- Regulation of gene expression by growth hormoneMolecular and Cellular Endocrinology, 2020
- Mass Spectrometry-Based Analysis of IGF-1 and hGH2009
- Growth hormone isoformsGrowth Hormone & IGF Research, 2009